Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Freenome
MedTech
Freenome to go public in $330M SPAC deal
Backed by an affiliate of Perceptive Advisors and joined by RA Capital, the move includes a commitment of $240 million in equity investments.
Conor Hale
Dec 5, 2025 10:35am
Ovid eyes next chapter with CEO transition—Chutes & Ladders
Nov 14, 2025 8:30am
J&J innovator vaults to Valo—Chutes & Ladders
Apr 11, 2025 8:30am
Roche leads Freenome's $254M fundraising for cancer blood tests
Feb 15, 2024 10:27am
Freenome picks up fellow cancer test maker Oncimmune for $16M
May 22, 2023 11:45am
JPM23: What's medtech's place at the conference? CEOs weigh in
Jan 12, 2023 9:45am
